These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
135 related articles for article (PubMed ID: 16126628)
1. Validation of rat endometriosis model by using raloxifene as a positive control for the evaluation of novel SERM compounds. Yao Z; Shen X; Capodanno I; Donnelly M; Fenyk-Melody J; Hausamann J; Nunes C; Strauss J; Vakerich K J Invest Surg; 2005; 18(4):177-83. PubMed ID: 16126628 [TBL] [Abstract][Full Text] [Related]
2. LY353381.HCl: a novel raloxifene analog with improved SERM potency and efficacy in vivo. Sato M; Turner CH; Wang T; Adrian MD; Rowley E; Bryant HU J Pharmacol Exp Ther; 1998 Oct; 287(1):1-7. PubMed ID: 9765314 [TBL] [Abstract][Full Text] [Related]
3. Oestrogen-induced epithelial-mesenchymal transition of endometrial epithelial cells contributes to the development of adenomyosis. Chen YJ; Li HY; Huang CH; Twu NF; Yen MS; Wang PH; Chou TY; Liu YN; Chao KC; Yang MH J Pathol; 2010 Nov; 222(3):261-70. PubMed ID: 20814901 [TBL] [Abstract][Full Text] [Related]
4. Effects of SP500263, a novel selective estrogen receptor modulator, on bone, uterus, and serum cholesterol in the ovariectomized rat. Sutherland MK; Brady H; Gayo-Fung LM; Leisten J; Lipps SG; McKie JA; O'Leary E; Patnaik N; Anderson DW; Bhagwat SS; Stein B Calcif Tissue Int; 2003 Jun; 72(6):710-6. PubMed ID: 14563000 [TBL] [Abstract][Full Text] [Related]
5. Raloxifene and/or estradiol decrease anxiety-like and depressive-like behavior, whereas only estradiol increases carcinogen-induced tumorigenesis and uterine proliferation among ovariectomized rats. Walf AA; Frye CA Behav Pharmacol; 2010 May; 21(3):231-40. PubMed ID: 20480545 [TBL] [Abstract][Full Text] [Related]
6. Testosterone attenuates and the selective estrogen receptor modulator, raloxifene, potentiates amphetamine-induced locomotion in male rats. Purves-Tyson TD; Boerrigter D; Allen K; Zavitsanou K; Karl T; Djunaidi V; Double KL; Desai R; Handelsman DJ; Weickert CS Horm Behav; 2015 Apr; 70():73-84. PubMed ID: 25747465 [TBL] [Abstract][Full Text] [Related]
7. A SERM increasing the expression of the osteoblastogenesis and mineralization-related proteins and improving quality of bone tissue in an experimental model of osteoporosis. Yogui FC; Momesso GAC; Faverani LP; Polo TOB; Ramalho-Ferreira G; Hassumi JS; Rossi AC; Freire AR; Prado FB; Okamoto R J Appl Oral Sci; 2018; 26():e20170329. PubMed ID: 29742257 [TBL] [Abstract][Full Text] [Related]
8. Biological activities of a novel selective oestrogen receptor modulator derived from raloxifene (Y134). Ning M; Zhou C; Weng J; Zhang S; Chen D; Yang C; Wang H; Ren J; Zhou L; Jin C; Wang MW Br J Pharmacol; 2007 Jan; 150(1):19-28. PubMed ID: 17115070 [TBL] [Abstract][Full Text] [Related]
9. A 12-month comparative study of raloxifene, estrogen, and placebo on the postmenopausal endometrium. Goldstein SR; Scheele WH; Rajagopalan SK; Wilkie JL; Walsh BW; Parsons AK Obstet Gynecol; 2000 Jan; 95(1):95-103. PubMed ID: 10636510 [TBL] [Abstract][Full Text] [Related]
10. Structure-activity relationships for a family of benzothiophene selective estrogen receptor modulators including raloxifene and arzoxifene. Overk CR; Peng KW; Asghodom RT; Kastrati I; Lantvit DD; Qin Z; Frasor J; Bolton JL; Thatcher GR ChemMedChem; 2007 Oct; 2(10):1520-6. PubMed ID: 17654759 [TBL] [Abstract][Full Text] [Related]
11. Vaginal effects of ospemifene in the ovariectomized rat preclinical model of menopause. Unkila M; Kari S; Yatkin E; Lammintausta R J Steroid Biochem Mol Biol; 2013 Nov; 138():107-15. PubMed ID: 23665515 [TBL] [Abstract][Full Text] [Related]
12. Evidence for an estrogen-like action of raloxifene upon the hypothalamic-pituitary unit: raloxifene inhibits luteinizing hormone secretion and stimulates prolactin secretion in ovariectomized female rats. Pinilla L; Gonzalez LC; Tena-Sempere M; Aguilar E Neurosci Lett; 2001 Oct; 311(3):149-52. PubMed ID: 11578816 [TBL] [Abstract][Full Text] [Related]
13. [Effect of bazedoxifene on endometriosis in a rat model]. Lyu H; Liu Y; Dang Q; Chen H; Chen R Zhonghua Fu Chan Ke Za Zhi; 2015 Apr; 50(4):291-5. PubMed ID: 26080942 [TBL] [Abstract][Full Text] [Related]
14. Therapeutically relevant concentrations of raloxifene dilate pressurized rat resistance arteries via calcium-dependent endothelial nitric oxide synthase activation. Chan YC; Leung FP; Wong WT; Tian XY; Yung LM; Lau CW; Tsang SY; Yao X; Chen ZY; Huang Y Arterioscler Thromb Vasc Biol; 2010 May; 30(5):992-9. PubMed ID: 20185791 [TBL] [Abstract][Full Text] [Related]
15. The effects of estrogen and raloxifene treatment on antioxidant enzymes in brain and liver of ovarectomized female rats. Ozgönül M; Oge A; Sezer ED; Bayraktar F; Sözmen EY Endocr Res; 2003 May; 29(2):183-9. PubMed ID: 12856805 [TBL] [Abstract][Full Text] [Related]
16. [What can we expect of raloxifene in the treatment of postmenopausal osteoporosis--views of a gynecologist]. Chmel R; Rob L; Strnad P Ceska Gynekol; 2002 Jul; 67(4):187-91. PubMed ID: 12373918 [TBL] [Abstract][Full Text] [Related]
17. Raloxifene, a selective estrogen receptor modulator, induces mitochondria-mediated apoptosis in human endometrial carcinoma cells. Morishima S; Shibata MA; Ohmichi M; Otsuki Y Med Mol Morphol; 2008 Sep; 41(3):132-8. PubMed ID: 18807138 [TBL] [Abstract][Full Text] [Related]
18. Renoprotective effects of a selective estrogen receptor modulator, raloxifene, in an animal model of diabetic nephropathy. Dixon A; Wells CC; Singh S; Babayan R; Maric C Am J Nephrol; 2007; 27(2):120-8. PubMed ID: 17308373 [TBL] [Abstract][Full Text] [Related]
19. Estrogenic properties of raloxifene, but not tamoxifen, on D2 and D3 dopamine receptors in the rat forebrain. Landry M; Lévesque D; Di Paolo T Neuroendocrinology; 2002 Oct; 76(4):214-22. PubMed ID: 12411738 [TBL] [Abstract][Full Text] [Related]
20. Comparative study of tamoxifen and raloxifene on endometrial cell proliferation of female rats in persistent estrus. Rodrigues Junior DM; Dos Santos AR; Lopes Costa PV; da Silva BB Int J Gynecol Cancer; 2012 Jan; 22(1):30-4. PubMed ID: 21892088 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]